Alveolar Type 2 Cells Guide

Overview

Pulmonary surfactant-producing alveolar type 2 cells differentiated from UCT-WJ-MSCs; designed for lung repair in COPD, pulmonary fibrosis, ARDS, and post-COVID lung damage

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Specs	Details
Source	Derived from P2 UCT-WJ-MSCs via lung-directed differentiation
Differentiation Protocol	Activin-A (endoderm) → Wnt BMP-4 (anterior foregut) → FGF10 retinoic acid (lung specification) → EGF dexamethasone (AT2 maturation)
Cryopreservation	DMSO-free, glucose-based
Post-Thaw Viability	>98%
Storage	−80 °C long-term; −196 °C LN2 vapor phase for extended storage
Identity Markers	SP-C⁺ (surfactant protein C), SP-B⁺, NKX2.1⁺ (thyroid transcription factor-1), ABCA3⁺, EpCAM⁺
Release Criteria	Surfactant secretion confirmed by ELISA prior to release
Immunogenicity	HLA-DR⁻ (retained from UCT-WJ-MSC origin); immune-privileged for allogeneic IV or intratracheal delivery without immunosuppression
Passage Limit	≤P2 from UCT-WJ-MSC
Manufacturing	cGMP, animal-product-free

Clinical Overview

Chronic and acute lung diseases remain leading causes of global mortality, with limited regenerative therapeutic options. Alveolar Type 2 (AT2) cells are the 'stem cells of the alveolar epithelium'^[1] — capable of self-renewal and differentiation into Type 1 alveolar cells (gas exchange surface). In COPD, IPF, ARDS, and post-COVID lung injury, AT2 cell depletion, dysfunction, and replacement by fibrotic tissue are core pathological events. Akira AT2 Cells, manufactured from the same UCT-WJ-MSC platform underlying the rest of this product line^[2], reconstitute this critical progenitor population through direct engraftment, restoration of surfactant production (reducing alveolar collapse), anti-fibrotic paracrine effects (TGF-β suppression, anti-fibrotic miRNAs), and immunomodulation of the alveolar macrophage environment. Immune privilege enables IV delivery without immunosuppression, a route well precedented in ARDS MSC trials^[3]; intratracheal delivery and application to the COPD pulmonary immune environment follow the same rationale but are less directly evidenced. A Phase 2 RCT (NCT04869397) of WJ-MSCs for COVID-19 respiratory complications provides direct precedent for this product line's clinical utility.^[4]

Process

Mechanism of Action

Surfactant Production: SP-C+/SP-B+ AT2 cells synthesize and secrete phospholipid-rich pulmonary surfactant, reducing alveolar surface tension, preventing microatelectasis, and improving oxygenation in ARDS and post-injury lungs.

Alveolar Epithelial Regeneration: AT2 cells are the progenitors of AT1 pneumocytes^[5] — the thin gas exchange surface cells covering more than 95% of the alveolar surface^[6]. AT2 cells divide and differentiate into Type 1 alveolar cells (AGER+, T1α+) to replace the gas exchange epithelial surface lost in ARDS and IPF — directly restoring lung architecture.

Anti-Fibrotic Paracrine Action: TGF-β pathway suppression via decorin, miR-29 and miR-200 (anti-fibrotic master miRNAs suppressing collagen and EMT gene expression)^[7], and HGF secretion^[8] slows the fibroblast-to-myofibroblast transition^[9] and reduces collagen deposition in IPF and post-ARDS remodeling; prostaglandin E2 further suppresses alveolar myofibroblast differentiation via EP2 receptor signaling.^[10]

Immunomodulation of Alveolar Macrophages: IL-10 and PGE2 secretion shifts alveolar macrophages from M1 (inflammatory) to M2 (pro-repair) phenotype — reducing neutrophil-driven lung damage in ARDS and COVID-19 pneumonia.

VEGF-Mediated Angiogenesis: Restoration of alveolar-capillary coupling via VEGF secretion promotes revascularization of fibrotic zones and improves ventilation-perfusion matching.

Biomarkers

Key Biomarkers & Molecular Cargo

Marker / Molecule	Functional Role
SP-C (Surfactant Protein C)	AT2-specific marker; essential for surfactant film stability
SP-B (Surfactant Protein B)	Co-secreted surfactant protein; prevents alveolar collapse
NKX2.1 (TTF-1)	Master lung transcription factor; AT2 identity and surfactant gene regulation
ABCA3	Lamellar body phospholipid transporter; surfactant packaging
EpCAM / E-Cadherin	Epithelial adhesion markers; confirm AT2 epithelial identity and cell-cell junction formation
miR-29 / miR-200	Anti-fibrotic miRNAs; suppress TGF-β, COL1A1, COL3A1 expression
HGF	Hepatocyte Growth Factor — potent anti-fibrotic and regenerative factor in lung
IL-10 / PGE2	Immunosuppressive molecules; shift alveolar macrophage to M2 repair phenotype
VEGF-A	Alveolar-capillary revascularization factor

Applications

Potential Applications

COPD / Emphysema: MSC-derived alveolar progenitor engraftment and surfactant-protein restoration have been demonstrated in preclinical elastase-induced emphysema models^[11]; AT2-cell-specific reconstitution and pattern-specific (centrilobular vs. panlobular) effects in human COPD remain unconfirmed.
Idiopathic Pulmonary Fibrosis (IPF): HGF/miR-29-mediated anti-fibrotic action; AT2 progenitor restoration replacing senescent AT2 cells driving IPF progression.
ARDS (Any Etiology): Surfactant restoration, alveolar epithelial regeneration, and macrophage M2 polarization — addressing the three core ARDS pathological elements.
Post-COVID Lung Damage: MSC therapy attenuates AT2 cell senescence and reduces fibrotic outcomes in preclinical bleomycin-induced pulmonary fibrosis models.
Cystic Fibrosis: Airway epithelial support, mucus clearance assistance, anti-inflammatory paracrine action.
Asthma: Airway remodeling prevention, epithelial barrier restoration, anti-inflammatory (IL-10, PGE2).
Lung Transplant Support: Donor lung repair prior to transplant; post-transplant primary graft dysfunction mitigation — an application consistent with the first-in-man MSC study in chronic lung allograft dysfunction.^[12]

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Evidence

Clinical & Preclinical Evidence

A WJ-MSC RCT in COVID-19 ARDS (n=100, double-blind, 28-day follow-up) significantly reduced 28-day mortality and improved lung CT infiltration scores, IL-6, and CRP versus placebo — a direct precedent for AB AT2 Cells in COVID-related lung injury.^[4]

A Phase 2 RCT (NCT04869397, McGill University Health Centre) using WJ-MSCs in COVID-19 respiratory complications further demonstrated the immunomodulatory and anti-fibrotic mechanisms central to Akira AT2 Cell function.^[13]

Preclinical bleomycin-induced IPF mouse models and LPS-induced ARDS models of AT2 cell administration report reduced fibrosis scores and collagen content, improved lung compliance, and reduced alveolar protein leakage and surfactant cell loss — directionally consistent with the broader translational evidence base for MSC-derived cell therapies^[14], though this specific preclinical evidence is not yet tied to a single verifiable published source and should be treated as supportive rather than quantitatively definitive.

The biological rationale for AT2 therapy in post-COVID lung damage is supported by pathological autopsy studies confirming AT2 cell depletion as a primary lesion in COVID-19 pneumonia^[15], with surviving AT2 cells exhibiting dysfunction, DNA damage, and accelerated senescence^[16] — restoration of this pool is intended to directly address that pathology.

Alveolar Type 2 Cells